Bank Of America Corp Metacrine, Inc. Transaction History

Bank Of America Corp

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	BUY	$0.35 - $0.46 $14 - $18	40 New	40 $0
Q1 2022 May 16, 2022	BUY	$0.43 - $0.7 $10,734 - $17,474	24,964 Added 10.47%	263,340 $161,000
Q4 2021 Feb 08, 2022	BUY	$0.64 - $3.83 $106,926 - $639,885	167,072 Added 234.31%	238,376 $161,000
Q3 2021 Nov 15, 2021	BUY	$2.61 - $3.84 $95,348 - $140,282	36,532 Added 105.06%	71,304 $244,000
Q2 2021 Sep 13, 2021	BUY	$3.37 - $5.73 $117,181 - $199,243	34,772 New	34,772 $132,000

Ticker MTCR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,569,500
Description
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

Stay updated on Bank Of America Corp with notifications on news.